Effects of captopril on ischemic events after myocardial infarction: Results of the survival and ventricular enlargement trial

  • Rutherford J
  • Pfeffer M
  • Moyé L
 et al. 
  • 16


    Mendeley users who have this article in their library.
  • 283


    Citations of this article.


Background In the Survival and Ventricular Enlargement (SAVE) trial, recurrent myocardial infarction (MI) was the most important predictor of a poor outcome and conferred a sevenfold increase in risk of death. The purpose of this study was to determine the predictors of recurrent MI in study participants and to examine the influence of the angiotensin- converting enzyme inhibitor captopril on this and other myo- cardial ischemic events. Methods and Results The 2231 patients had survived the acute phase of MI (3 to 16 days) and had a radionuclide ventricular ejection fraction

Author-supplied keywords

  • angioplasty
  • bypass
  • captopril
  • ischemia
  • myocardial infarction

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • John D. Rutherford

  • Marc A. Pfeffer

  • Lemuel A. Moyé

  • Barry R. Davis

  • Greg C. Flaker

  • Peter R. Kowey

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free